Security Risk Management for Medical Devices: MDR & IVDR Compliance Whitepaper

REPHINE SPEECH MARKS OPEN MEDICALDEVICES

Cybersecurity is no longer a feature—it’s a fundamental aspect of safety, effectiveness, and patient trust. SRM must be integrated from design through decommissioning.

REPHINE SPEECH MARKS CLOSE MEDICALDEVICES

About this Whitepaper

As medical devices become increasingly digital, they face growing exposure to cybersecurity risks—posing potential threats to patient safety and regulatory compliance.

This white paper offers a comprehensive, practical guide to Security Risk Management (SRM) throughout the Total Product Lifecycle (TPLC), covering:

  • Integration of cybersecurity in compliance with EU MDR 2017/745 and IVDR 2017/746
  • Alignment with FDA and IMDRF cybersecurity expectations
  • Use of threat modelling (STRIDE) and SBOMs for risk analysis
  • Security V&V activities including penetration testing and vulnerability scanning
  • Postmarket risk management and coordinated vulnerability disclosure

Whether you’re preparing a technical file, improving postmarket surveillance, or building secure-by-design software, this guide helps ensure your devices meet state-of-the-art standards like IEC 81001-5-1 and stay compliant with international regulations.

Who Should Read This?

  • Medical Device Regulatory & QA Professionals

  • Product Development & Cybersecurity Teams

  • Design Engineers & Risk Managers

  • EU MDR / IVDR Compliance Officers

Hero Image Software Testing Guide MedTech

View our other resources and company news

BANNER Practical Guide to Post Market Surveillance PMS under EU MDR IVDR CSV

Practical Guide to the EMA’s Draft EU GMP Revisions

The EU’s new Product Liability Directive (2024/2853) changes who can be held liable and what damages can be claimed. From software and data loss to ...
Read More
BANNER Practical Guide to Post Market Surveillance PMS under EU MDR IVDR Guide

Practical Guide to Post-Market Surveillance (PMS) under EU MDR/IVDR

The EU’s new Product Liability Directive (2024/2853) changes who can be held liable and what damages can be claimed. From software and data loss to ...
Read More
GMP Raising the bar Blog series Header image May 25 Blog

AI for Pharmaceutical SOPs: Transforming Quality Management and Compliance

Rephine helps pharmaceutical and biotech companies transition to digital QMS platforms like Veeva Vault, MasterControl, or TrackWise. From vendor-neutral selection to full GxP-compliant validation and ...
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan CAPA

Strengthening CAPA & Exceptions Management

Learn how Rephine’s tailored GxP training helped a pharmaceutical manufacturer strengthen CAPA effectiveness, improve compliance, and boost team confidence.
Read More
GMP Raising the bar Blog series Header image May 25 Blog

EU GMP Annex 1 vs FDA Aseptic Guide: Bridging Compliance

EU and U.S. regulators share the same sterility assurance goals, but their approaches differ. Learn how to align Annex 1 and FDA guidance to streamline ...
Read More
GMP Raising the bar Blog series Header image May 25 Blog

GMP & GDP: Ensuring Quality in Drug Storage and Transport

Storage and transport aren’t just logistics — they’re critical GMP processes. Discover how USP helps pharma companies manage risk and maintain quality across global ...
Read More
GMP Raising the bar Blog series Header image May 25 Blog

Blockchain for GMP Documentation: Hype or Future Reality?

Blockchain promises immutability, traceability, and transparency for GMP documentation. But is it a compliance game-changer — or just hype?
Read More
Medical Device Guide

Is Your Insurance Policy Ready for the New EU Product Liability Directive?

The EU’s new Product Liability Directive (2024/2853) changes who can be held liable and what damages can be claimed. From software and data loss to ...
Read More
News update: 100% drug tariffs in the USA impacting pharmaceutical supply chains and compliance Article

100% Drug Tariffs in the U.S. – Impact on Pharma Supply Chains & Compliance

The U.S. has announced sweeping 100% tariffs on patented medicines, disrupting pharma supply chains and market access. Discover what this means for manufacturers — and ...
Read More
Contact Us

Strengthen Your Assurance Journey

GMP Chapter 22 Adapting to Hybrid Documentation Standards